We provide you with 20 years of free, institutional-grade data for GNLX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GNLX. Explore the full financial landscape of GNLX stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2023-11-14 | 1231457 | GNLX | 10-Q | Url |
| 2023-08-14 | 1231457 | GNLX | 10-Q | Url |
| 2023-06-28 | 1231457 | GNLX | S-1 | Url |
| 2023-05-15 | 1231457 | GNLX | 10-Q | Url |
| 2023-03-29 | 1231457 | GNLX | 10-K | Url |
| 2022-06-24 | 1231457 | GNLX | S-1 | Url |
Genelux Corp.(NASDAQ:GNLX) 
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vac...
Website: https://www.genelux.com
Founded: 2001
IPO Price: $6 (Jan 26, 2023)
Full Time Employees: 15
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about GNLX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.